New Delhi, November 13, 2026 (Yes Punjab News)
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed strict monitoring of revised prices for 137 non-scheduled anti-cancer medicines following the implementation of Trade Margin Rationalisation (TMR) from November 9.
According to an official statement issued on Friday, manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been directed to comply with the revised prices and prominently display updated price lists at their premises and on their websites.
The latest revised price lists, based on submissions received from companies up to November 11, 2026, are available on the NPPA website and the Pharma Sahi Daam app and portal.
State Drug Controllers (SDCs) have been asked to monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that patients receive the benefit of lower maximum retail prices (MRPs). Violations may invite overcharging proceedings under the Drugs (Prices Control) Order, 2013.
Patients can report complaints regarding overcharging, shortages or non-availability of medicines through the Pharma Sahi Daam app or portal, the NPPA helpline or email. State Drug Controllers have been directed to submit their Action Taken Reports to the NPPA by November 16, 2026.
The Centre has introduced a 30 per cent cap on trade margins for the 137 non-scheduled anti-cancer medicines. Through an order dated October 17, the NPPA brought these drugs under the TMR mechanism, limiting trade margins across the supply chain.
By November 9, a total of 85 pharmaceutical companies had reported revised MRPs for 121 of the 137 medicines, covering 1,366 stock-keeping units. The highest reported price reduction was 96.45 per cent, while more than 650 formulations recorded reductions exceeding 50 per cent. Most reductions fell in the 50–75 per cent range.
The estimated savings for patients stand at Rs 3,541 crore. The calculation is based on the difference between original and revised prices applied to sales volumes recorded between April 2025 and March 2026.
The 30 per cent margin cap applies to the listed medicines across retail and hospital pharmacies, covering different dosages and forms, including tablets and injections, as well as medicines sold individually or in combinations.
FOLLOW NOW
